미숙아 동맥관 개존증에서 인도메타신 정맥 투여의 치료 성적에 대한 분석 = Analysis of Therapeutic Effect of Intravenous Indomethacin in Preterm Infants with Patent Ductus Arteriosus

다국어 초록 (Multilingual Abstract)

Objective: The aims of this study were to determine the response of patent ductus arteriosus(PDA) and side effects to intravenous indomethacin therapy.
Methods and Materials: From January 1999 to December 2000, 24 preterm infants diagnosed as significant PDA based on clinical and echocardiographic findings in NICU at Seoul Paik Hospital were analysed retrospectively for clinical effects and complications of intravenous indomethacin therapy.
Results: The PDA was closed in 12(50%) and constricted in 10(42%) among total patients initially. Only one of 10 constricted infants was reopened. Second courses of indomethacin therapy were repeated in three patients showing poor responses, resulting in 67%(2/3) of PDA closure rate. Eventually, indomethacin therapy was successful in 22(92%) neonates, except 2 patients(8.3%) requiring PDA ligation. The side effects of indomethacin were transient hyponatremia(62.5%) and oliguria(4.2%). Total mortality rate was 12.5%(3/24), and only 1 case with pulmonary hemorrhage seemed to be possibly related to indomethacin therapy.
Conclusions: The results of our study confirm that a significantly high PDA closure rate can be achieved by intravenous indomethacin administration. We conclude that intravenous indomethacin therapy can be the first method of treatment in premature infants with PDA, despite the transient renal side effects.